MRI-guided radiation therapy for early-stage kidney cancer
This trial tests a new way to deliver radiation to kidney tumors using MRI guidance. It aims to treat early-stage kidney cancer while sparing healthy tissue, and may be an option for people who cannot have surgery or prefer not to.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have early-stage kidney cancer (tumor smaller than 7 cm) that has not spread to other parts of the body.
- You are considered not a good candidate for surgery or ablation, or you choose not to have those treatments.
- You are able to undergo MRI scans (no severe claustrophobia or incompatible implants).
- You have adequate kidney function (eGFR of 30 or higher).
- You have a life expectancy of at least 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of precise radiation therapy for kidney cancer. It uses a special scanner to guide the treatment without needing a marker, which may make the procedure quicker and more comfortable.
This trial tests whether CyberKnife (high-precision radiation) can treat early-stage kidney cancer. It may help people avoid or delay more invasive treatments by targeting the tumor while protecting nearby organs.
This trial uses a precise form of radiation therapy called stereotactic body radiotherapy (SBRT) that tracks the tumor during treatment to destroy kidney tumors without surgery. It may be an option if you have a kidney tumor (primary or spread from another cancer) up to 10 cm in size and you haven't had radiation to that area before.
This trial tests a precise type of radiation therapy for small, early-stage kidney tumors that cannot be surgically removed or are at high risk for surgery. It aims to offer an alternative treatment with fewer side effects.
This study tests whether MRI scans can help doctors make better decisions about treatment for small kidney tumors. If you have a kidney mass up to 4 cm and are planning surgery, you may be able to join.
This trial tests whether targeted, high-precision radiation (stereotactic radiotherapy) can control a small number of growing kidney cancer metastases while you continue systemic treatment. It may help people who have “oligoprogressive” disease, where only 1–3 spots are getting worse.
Hear when a new Primary Renal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.